24 November 2020 | News
ZUCAPRIDE –M comes in two strengths ZUCAPRIDE –M 500 priced at Rs 12.80 per tablet and ZUCAPRIDE –M 1000 at Rs 14.80 against Rs 57.70 and 59.80 of existing brands in the market
Micro Labs, based in Bengaluru, has announced the launch of anti-diabetic drug combo Dapagliflozin plus Metformin tablets under the brand name ZUCAPRIDE- M. ZUCAPRIDE –M comes in two strengths ZUCAPRIDE –M 500 priced at Rs 12.80 per tablet and ZUCAPRIDE –M 1000 at Rs 14.80 against Rs 57.70 and 59.80 of existing brands in the market. In terms of monthly savings, a patient can save up to Rs 1347 when prescribed Zucapride M 500 & Rs 1350 when prescribed Zucapride M 1000.
"Diabetes is a key area of focus for Micro Labs and with this launch, the company aims to access the 1000 Crs SGLT2 inhibitors market, by providing an effective, high quality and world-class treatment option to patients in India. Besides, strong R&D efforts have helped us develop our own API which is at par with the innovator brand,” says Ashok Jain, Executive Director, Micro Labs Ltd.
ZUCAPRIDE- M, a once-daily oral treatment indicated as an adjunct to diet and exercise, aims to improve glycaemic control in adults with type 2 diabetes. ZUCAPRIDE -M contains two active pharmaceutical ingredients (APIs) Dapagliflozin, a novel anti-diabetic class called sodium-glucose co-transporter 2 (SGLT2) inhibitor & Metformin, a widely prescribed oral anti-diabetic drug.
“This combination is set to gain acceptance as second line therapy for the management of diabetes owing to the large amount of published dapagliflozin data on cardio-renal safety and weight loss in diabetes individuals besides reduction of blood glucose levels” as per Dr S Manjula, Sr VP, Medical Services, Micro Labs Ltd.